Cheng Sohanya Roshan 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) EVP Cheng Sohanya Roshan Receives 32,415 RSUs
What Happened
Cheng Sohanya Roshan, EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc. (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The award was granted at $0.00 (RSUs convert one-for-one into common shares) and is reported as a grant (transaction code A) — not a market purchase or sale.
Key Details
- Transaction date: January 31, 2026; filing date: February 3, 2026 (Form 4 accession 0001193125-26-035687). Filing appears to be within the normal Form 4 reporting window.
- Grant amount: 32,415 RSUs; per the filing the acquisition price is $0.00 (award).
- Vesting: 50% of the RSUs vest on January 31, 2027; the remaining 50% vest on January 31, 2028 (see footnote F1). RSUs convert 1-for-1 into common stock when vested.
- Shares owned after transaction: not specified in the supplied filing details.
- Notable footnote: F1 describes the RSU award and the two-date vesting schedule. No 10b5-1, tax-withholding sale, or cashless exercise noted.
Context
This was an equity compensation award to an executive (a routine corporate compensation action) rather than a buy or sell signal. RSU grants reflect compensation/retention and will only result in actual shares if and when the awards vest.
Insider Transaction Report
Form 4
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
[F1]2026-01-31+32,415→ 111,921 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.
Signature
/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng|2026-02-03